Windtree Therapeutics, Inc. (WINT) - NASDAQ
  • Mar. 7, 2012, 11:38 AM

    Discovery Labs (DSCO +17.9%) could be acquired, speculates Roth Capital. Following the approval of its synthetic surfactant, Surfaxin, by the FDA, Roth says the company could sell itself, or obtain a partner. It raises its target on the shares to $10 from $6 while maintaining its Buy rating.

    | Mar. 7, 2012, 11:38 AM | 3 Comments
Company Description
Discovery Laboratories, Inc. is engaged in the manufacture and development of products for infants and respiratory diseases. It focuses on producing surfactant replacement therapies for patients with respiratory disease and neonatology for the improvement of respiratory distress syndrome for... More
Sector: Healthcare
Industry: Biotechnology
Country: United States